Full Text View
Tabular View
No Study Results Posted
Related Studies
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
This study is ongoing, but not recruiting participants.
Study NCT01258933   Information provided by M.D. Anderson Cancer Center

First Received on December 9, 2010.   Last Updated on March 13, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Lymphoma
Additional conditions recognized in this trial
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasm, Residual
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplastic Processes
Pathologic Processes
Interventions listed in this trial
Ofatumumab
Sponsors listed in this trial
M.D. Anderson Cancer Center
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services